The FDA has approved Inlexzo (gemcitabine intravesical system) for the treatment of adult patients with BCG-unresponsive, non-muscle invasive bladder cancer with CIS with or without papillary tumors.

The U.S. Food and Drug Administration has approved Johnson & Johnson's drug delivery system for a type of bladder cancer, ...

A new drug-releasing system, TAR-200, eliminated tumors in 82% of patients in a phase 2 clinical trial for individuals with high-risk non-muscle-invasive bladder cancer whose cancer had previously ...